Posted by Michael Wonder on 29 Jan 2019
Pfizer launches China's first pay for performance model for cancer
26 January 2019 - Pfizer launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China. The program is the nation's first pay-for-performance insurance for oncology and covers 34 Chinese cities.
Pfizer developed the Bo'ai Xin'an - Patient Benefit Management Program in collaboration with insurance company Shanghai Branch of PICC Health Insurance and medical payment services company Shanghai MediTrust Health.
It will reimburse enrolled patients up to 33.5% of their Ibrance treatment cost if they experience disease progression or metastasis within the first 126 days of starting treatment with Ibrance in combination with an aromatase inhibitor.
